Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Jakubowska, ARozkrut, D
Antoniou, A
Hamann, U
Scott, R J
McGuffog, L
Healy, S
Sinilnikova, O M
Rennert, G
Lejbkowicz, F
Flugelman, A
Andrulis, I L
Glendon, G
Ozcelik, H
Thomassen, M
Paligo, M
Aretini, P
Kantala, J
Aroer, B
von Wachenfeldt, A
Liljegren, A
Loman, N
Herbst, K
Kristoffersson, U
Rosenquist, R
Karlsson, P
Stenmark-Askmalm, M
Melin, B
Nathanson, K L
Domchek, S M
Byrski, T
Huzarski, T
Gronwald, J
Menkiszak, J
Cybulski, C
Serrano, P
Osorio, A
Cajal, T R
Tsitlaidou, M
Benítez, J
Gilbert, M
Rookus, M
Aalfs, C M
Kluijt, I
Boessenkool-Pape, J L
Meijers-Heijboer, H E J
Oosterwijk, J C
van Asperen, C J
Blok, M J
Nelen, M R
van den Ouweland, A M W
Seynaeve, C
van der Luijt, R B
Devilee, P
Easton, D F
Peock, S
Frost, D
Platte, R
Ellis, S D
Fineberg, E
Evans, D G
Lalloo, F
Eeles, R
Jacobs, C
Adlard, J
Davidson, R
Eccles, D
Cole, T
Cook, J
Godwin, A
Bove, B
Stoppa-Lyonnet, D
Caux-Moncoutier, V
Belotti, M
Tirapo, C
Mazoyer, S
Barjhoux, L
Boutry-Kryza, N
Pujol, P
Coupier, I
Peyrat, J-P
Vennin, P
Muller, D
Fricker, J-P
Venat-Bouvet, L
Johannsson, O Th
Isaacs, C
Schmutzler, R
Wappenschmidt, B
Meindl, A
Arnold, N
Varon-Mateeva, R
Niederacher, D
Sutter, C
Deissler, H
Preisler-Adams, S
Simard, J
Soucy, P
Durocher, F
Chenevix-Trench, G
Beesley, J
Chen, X
Rebbeck, T
Couch, F
Wang, X
Lindor, N
Fredericksen, Z
Pankratz, V S
Peterlongo, P
Bonanni, B
Fortuzzi, S
Peissel, B
Szabo, C
Mai, P L
Loud, J T
Lubinski, J
Issue Date
2012-06-05
Metadata
Show full item recordCitation
Br. J. Cancer 2012, 106 (12):2016-24Abstract
The variable penetrance of breast cancer in BRCA1/2 mutation carriers suggests that other genetic or environmental factors modify breast cancer risk. Two genes of special interest are prohibitin (PHB) and methylene-tetrahydrofolate reductase (MTHFR), both of which are important either directly or indirectly in maintaining genomic integrity. To evaluate the potential role of genetic variants within PHB and MTHFR in breast and ovarian cancer risk, 4102 BRCA1 and 2093 BRCA2 mutation carriers, and 6211 BRCA1 and 2902 BRCA2 carriers from the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA) were genotyped for the PHB 1630 C>T (rs6917) polymorphism and the MTHFR 677 C>T (rs1801133) polymorphism, respectively. There was no evidence of association between the PHB 1630 C>T and MTHFR 677 C>T polymorphisms with either disease for BRCA1 or BRCA2 mutation carriers when breast and ovarian cancer associations were evaluated separately. Analysis that evaluated associations for breast and ovarian cancer simultaneously showed some evidence that BRCA1 mutation carriers who had the rare homozygote genotype (TT) of the PHB 1630 C>T polymorphism were at increased risk of both breast and ovarian cancer (HR 1.50, 95%CI 1.10-2.04 and HR 2.16, 95%CI 1.24-3.76, respectively). However, there was no evidence of association under a multiplicative model for the effect of each minor allele. The PHB 1630TT genotype may modify breast and ovarian cancer risks in BRCA1 mutation carriers. This association need to be evaluated in larger series of BRCA1 mutation carriers.Description
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field.Additional Links
http://dx.doi.org/10.1038/bjc.2012.160http://www.nature.com/bjc/journal/vaop/ncurrent/abs/bjc2012160a.html
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388557/
Rights
Archived with thanks to British journal of cancerae974a485f413a2113503eed53cd6c53
10.1038/bjc.2012.160
Scopus Count
Collections
Related articles
- A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.
- Authors: Ding YC, McGuffog L, Healey S, Friedman E, Laitman Y, Paluch-Shimon S, Kaufman B, SWE-BRCA., Liljegren A, Lindblom A, Olsson H, Kristoffersson U, Stenmark-Askmalm M, Melin B, Domchek SM, Nathanson KL, Rebbeck TR, Jakubowska A, Lubinski J, Jaworska K, Durda K, Gronwald J, Huzarski T, Cybulski C, Byrski T, Osorio A, Cajal TR, Stavropoulou AV, Benítez J, Hamann U, HEBON., Rookus M, Aalfs CM, de Lange JL, Meijers-Heijboer HE, Oosterwijk JC, van Asperen CJ, Gómez García EB, Hoogerbrugge N, Jager A, van der Luijt RB, EMBRACE., Easton DF, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lalloo F, Izatt L, Eeles R, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Godwin AK, Pathak H, GEMO Study Collaborators., Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Barjhoux L, Léoné M, Gauthier-Villars M, Caux-Moncoutier V, de Pauw A, Hardouin A, Berthet P, Dreyfus H, Ferrer SF, Collonge-Rame MA, Sokolowska J, Buys S, Daly M, Miron A, Terry MB, Chung W, John EM, Southey M, Goldgar D, Singer CF, Tea MK, Gschwantler-Kaulich D, Fink-Retter A, Hansen TV, Ejlertsen B, Johannsson OT, Offit K, Sarrel K, Gaudet MM, Vijai J, Robson M, Piedmonte MR, Andrews L, Cohn D, DeMars LR, DiSilvestro P, Rodriguez G, Toland AE, Montagna M, Agata S, Imyanitov E, Isaacs C, Janavicius R, Lazaro C, Blanco I, Ramus SJ, Sucheston L, Karlan BY, Gross J, Ganz PA, Beattie MS, Schmutzler RK, Wappenschmidt B, Meindl A, Arnold N, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Nevanlinna H, Aittomäki K, Simard J, KConFab Investigators., Spurdle AB, Beesley J, Chen X, Tomlinson GE, Weitzel J, Garber JE, Olopade OI, Rubinstein WS, Tung N, Blum JL, Narod SA, Brummel S, Gillen DL, Lindor N, Fredericksen Z, Pankratz VS, Couch FJ, Radice P, Peterlongo P, Greene MH, Loud JT, Mai PL, Andrulis IL, Glendon G, Ozcelik H, OCGN., Gerdes AM, Thomassen M, Jensen UB, Skytte AB, Caligo MA, Lee A, Chenevix-Trench G, Antoniou AC, Neuhausen SL, Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
- Issue date: 2012 Aug
- The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multicenter study among 15,542 BRCA1 and BRCA2 mutation carriers.
- Authors: Jakubowska A, Rozkrut D, Antoniou A, Hamann U, Lubinski J
- Issue date: 2010 Jun
- Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.
- Authors: Engel C, Versmold B, Wappenschmidt B, Simard J, Easton DF, Peock S, Cook M, Oliver C, Frost D, Mayes R, Evans DG, Eeles R, Paterson J, Brewer C, Epidemiological Study of Familial Breast Cancer (EMBRACE)., McGuffog L, Antoniou AC, Stoppa-Lyonnet D, Sinilnikova OM, Barjhoux L, Frenay M, Michel C, Leroux D, Dreyfus H, Toulas C, Gladieff L, Uhrhammer N, Bignon YJ, Meindl A, Arnold N, Varon-Mateeva R, Niederacher D, Preisler-Adams S, Kast K, Deissler H, Sutter C, Gadzicki D, Chenevix-Trench G, Spurdle AB, Chen X, Beesley J, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab)., Olsson H, Kristoffersson U, Ehrencrona H, Liljegren A, Swedish Breast Cancer Study, Sweden (SWE-BRCA)., van der Luijt RB, van Os TA, van Leeuwen FE, Hereditary Breast and Ovarian cancer group Netherlands (HEBON)., Domchek SM, Rebbeck TR, Nathanson KL, Osorio A, Ramón y Cajal T, Konstantopoulou I, Benítez J, Friedman E, Kaufman B, Laitman Y, Mai PL, Greene MH, Nevanlinna H, Aittomäki K, Szabo CI, Caldes T, Couch FJ, Andrulis IL, Godwin AK, Hamann U, Schmutzler RK, Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
- Issue date: 2010 Nov
- Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.
- Authors: Ramus SJ, Kartsonaki C, Gayther SA, Pharoah PD, Sinilnikova OM, Beesley J, Chen X, McGuffog L, Healey S, Couch FJ, Wang X, Fredericksen Z, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Roversi G, Barile M, Viel A, Allavena A, Ottini L, Papi L, Gismondi V, Capra F, Radice P, Greene MH, Mai PL, Andrulis IL, Glendon G, Ozcelik H, OCGN., Thomassen M, Gerdes AM, Kruse TA, Cruger D, Jensen UB, Caligo MA, Olsson H, Kristoffersson U, Lindblom A, Arver B, Karlsson P, Stenmark Askmalm M, Borg A, Neuhausen SL, Ding YC, Nathanson KL, Domchek SM, Jakubowska A, Lubiński J, Huzarski T, Byrski T, Gronwald J, Górski B, Cybulski C, Dębniak T, Osorio A, Durán M, Tejada MI, Benítez J, Hamann U, Rookus MA, Verhoef S, Tilanus-Linthorst MA, Vreeswijk MP, Bodmer D, Ausems MG, van Os TA, Asperen CJ, Blok MJ, Meijers-Heijboer HE, HEBON., EMBRACE., Peock S, Cook M, Oliver C, Frost D, Dunning AM, Evans DG, Eeles R, Pichert G, Cole T, Hodgson S, Brewer C, Morrison PJ, Porteous M, Kennedy MJ, Rogers MT, Side LE, Donaldson A, Gregory H, Godwin A, Stoppa-Lyonnet D, Moncoutier V, Castera L, Mazoyer S, Barjhoux L, Bonadona V, Leroux D, Faivre L, Lidereau R, Nogues C, Bignon YJ, Prieur F, Collonge-Rame MA, Venat-Bouvet L, Fert-Ferrer S, GEMO Study Collaborators., Miron A, Buys SS, Hopper JL, Daly MB, John EM, Terry MB, Goldgar D, BCFR., Hansen Tv, Jønson L, Ejlertsen B, Agnarsson BA, Offit K, Kirchhoff T, Vijai J, Dutra-Clarke AV, Przybylo JA, Montagna M, Casella C, Imyanitov EN, Janavicius R, Blanco I, Lázaro C, Moysich KB, Karlan BY, Gross J, Beattie MS, Schmutzler R, Wappenschmidt B, Meindl A, Ruehl I, Fiebig B, Sutter C, Arnold N, Deissler H, Varon-Mateeva R, Kast K, Niederacher D, Gadzicki D, Caldes T, de la Hoya M, Nevanlinna H, Aittomäki K, Simard J, Soucy P, kConFab Investigators., Spurdle AB, Holland H, Chenevix-Trench G, Easton DF, Antoniou AC, Consortium of Investigators of Modifiers of BRCA1/2.
- Issue date: 2011 Jan 19
- Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks.
- Authors: Jakubowska A, Gronwald J, Menkiszak J, Górski B, Huzarski T, Byrski T, Edler L, Lubiński J, Scott RJ, Hamann U
- Issue date: 2007 Sep